ISRG · NASDAQ · CIK 0001035267
Intuitive Surgical, Inc.
Intuitive Surgical, Inc. holds 1 disclosed position, 0 of them carrying a sourced value and 1 that nobody has sized.
Intuitive Surgical, Inc. - Profile
- Sector
- Health CareGICS
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842
- Listed on
- Nasdaq
- Employees
- 17,021stated 2025
- Incorporated in
- Delaware
- Financial year ends
- 31 December
Source
Address, industry classification, listing and incorporation come from Intuitive Surgical, Inc.'s own SEC filer record, so the industry is the SEC's dry classification rather than a marketing label. The website comes from Wikidata. The headcount is the figure the Wikipedia article states for 2025, not a figure this site has verified against a filing. The description is the opening paragraph of its Wikipedia article, used under CC BY-SA 4.0.
Share price
ISRG
Description
Intuitive Surgical, Inc. is an American biotechnology company that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System. The company is part of the Nasdaq-100, S&P 100 and S&P 500. As of 31 December 2021, Intuitive Surgical had an installed base of 6,730 da Vinci Surgical Systems, including 4,139 in the U.S., 1,199 in Europe, 1,050 in Asia, and 342 in the rest of the world.
Equity stakes Intuitive Surgical, Inc. holds in other companies.
No position on this side carries a sourced value, so there is nothing to chart. The table still lists 1 of them.
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 2,274 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
2,274 managers reported a position, together holding 292.3m shares, or 82.5% of the company. The 40 largest are listed. Percentages are of the 354.2m shares outstanding at 15 Apr 2026, the count in force when this quarter was measured rather than the count today.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- Intuitive Surgical does not file Form 13F. Its EDGAR filing history for CIK 0001035267 (submissions JSON, checked 17 August 2026) contains no 13F-HR or 13F-NT of any vintage, consistent with it not acting as an institutional investment manager.
- The brief's premise of an Intuitive Surgical joint venture in India with Schneider Electric was checked against the FY2025 10-K, the Q2 FY2026 10-Q, and a web search, and could not be corroborated. Neither filing contains the word 'Schneider'. Intuitive's own 2018 press release describes India as a direct-operations market (a Bengaluru office absorbing employees from its 2017 Vattikuti Robotic Institute India acquisition), not a joint venture, and both 10-K and 10-Q list India only among the direct-sales countries, separate from the parenthetical naming the China Joint Venture. No India JV, with Schneider Electric or otherwise, is recorded here.
- The only named, percentage-disclosed joint venture found in the filings is the China Joint Venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.: Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd. and Intuitive Surgical-Fosun (HongKong) Co., Ltd., owned 60 percent by Intuitive and 40 percent by Fosun Pharma per the FY2025 10-K. Intuitive consolidates the Joint Venture as it holds a controlling financial interest; Fosun's 40 percent is reported as noncontrolling interest ($117.7 million at 31 December 2025, $129.3 million at 30 June 2026) inside Intuitive's own stockholders' equity, so this behaves more like a partly-owned consolidated subsidiary than a passive minority stake, but is recorded as a holding because the brief calls for any named JV with a disclosed percentage.
- Intuitive's 'equity investments without readily determinable fair value' were a single combined balance of $121.7 million at 31 December 2025 and $129.1 million at 30 June 2026 (per the roll-forward tables in the FY2025 10-K and Q2 FY2026 10-Q respectively). Neither filing names the underlying investees or splits the balance by counterparty, so per the brief's rule this combined figure sizes none of them; no individual private-company holding is recorded from it. The 10-K also states that during 2025 the Company held no equity investments with readily determinable fair values, and no us-gaap:EquityMethodInvestments concept exists in Intuitive's XBRL company-facts, so there is no equity-method investment separate from the JV above.
- In November 2025 Intuitive acquired (100 percent, immaterial consideration) a company developing robotics/AI tissue-assessment technology for biopsy; this is a wholly owned business combination, excluded from holdings per the brief. It is unrelated to the equity-investments balance above.
- Vanguard disagreement, recorded rather than resolved. The register uses Vanguard's own Form 13F-HR for the quarter ended 31 December 2025 (33,613,298 shares), the most recent quarter for which Vanguard filed a holdings report (13F-HR) rather than a notice. Vanguard filed Form 13F-NT (notice only) for the quarters ended 31 March 2026 and 30 June 2026 under CIK 0000102909, so no more recent Vanguard share count is available from that CIK; its Q1/Q2 2026 holdings are reported by other Vanguard reporting managers not identified within the time budget. Intuitive's own 13 March 2026 proxy separately cites Vanguard at 33,613,298 shares (9.5 percent), matching this register row exactly, because the proxy also sourced Vanguard's 29 January 2026 13F-HR.
- BlackRock disagreement, recorded rather than resolved. The register uses BlackRock, Inc.'s Form 13F-HR for the quarter ended 30 June 2026 (30,024,648 shares, filed 7 August 2026 under CIK 0002012383). Intuitive's 13 March 2026 proxy instead cites BlackRock at 30,516,154 shares (8.6 percent), sourced to BlackRock's 13F-HR filed 12 February 2026 for the quarter ended 31 December 2025, i.e. older data than the register row here.
- Percentages are computed by this research against stated share counts, not taken from the 13F filings themselves. The 30 June 2026 13F rows (BlackRock, State Street, Geode, Morgan Stanley, FMR, JPMorgan, Norges Bank) use 353,278,038 shares outstanding as of 16 July 2026 (Q2 FY2026 10-Q cover, dei:EntityCommonStockSharesOutstanding). The Vanguard row uses 355,130,237 shares as of 28 January 2026 (FY2025 10-K cover). The proxy-sourced insider rows use 355,052,975 shares as of 31 December 2025, the denominator the proxy itself states.
- No Schedule 13D or 13G/A has been filed on Intuitive Surgical common stock since 14 February 2024, per the EDGAR filing index for CIK 0001035267 (21 SC 13G/A filings total, most recent dated 14 February 2024). That removes the usual independent cross-check on the top holders' current stakes and is why the 13F route was used for the institutional rows.
- Intuitive Surgical has a single class of common stock, $0.001 par value, one class registered on Nasdaq under ISRG. There is no dual-class structure and no founder-control block: Gary Guthart, the highest-owning individual insider (co-founder-era executive, now Executive Chair of the Board), holds 0.43 percent with no enhanced voting rights.
- Insider rows overlap. The 'all executive officers and directors as a group (17 persons)' row of 2,260,608 shares (0.6 percent) contains the 15 individually listed insiders (summing to 2,233,959 shares) plus 2 further officers or directors not individually named; do not add the group row to the individual rows.
- Market capitalisation of $139.37 billion is the figure published on stockanalysis.com as of 14 August 2026. Cross-check: 353,278,038 shares at roughly $394-400 per share (per contemporaneous news coverage of the 14 August 2026 close) is consistent with this range.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- The specific private companies behind the $129.1 million (30 June 2026) / $121.7 million (31 December 2025) combined 'equity investments without readily determinable fair value' balance. Searched the equity-investments footnote in both the FY2025 10-K and the Q2 FY2026 10-Q in full; both give only a combined roll-forward table (beginning balance, fair-value changes, purchases/sales/other, ending balance) with no investee names or per-company amounts.
- Whether the India business (Intuitive India, direct operations since 2018) involves any joint-venture or minority-equity structure with a named partner. Searched both filings for 'India' and 'joint venture' together; India appears only in the list of direct-sales countries alongside the named China Joint Venture, never as its own JV. Also searched for 'Schneider' specifically (0 hits in either filing) and via a general web search, which found no evidence of an Intuitive Surgical/Schneider Electric relationship.
- Capital Group / Capital Research and T. Rowe Price positions could not be sourced within the time budget; the correct current 13F-filer CIKs for these managers were not identified and not checked.
- The 2 executive officers or directors included in the 17-person proxy aggregate but not individually named in the beneficial-ownership table (accounting for 26,649 of the 2,260,608 shares in that row).
- Intuitive's Q3 FY2026 10-Q (covering the quarter ending on or about 30 September 2026) was not yet filed as of 17 August 2026, so no equity-investment or Joint Venture activity from that quarter is reflected here.